Table 2 Cannabinoid use characteristics. To demonstrate feasibility and applicability of CannaCount, averages and standard deviations are provided for frequency of use and cannabinoid exposure using data from 150 total study visits (n = 60 medical cannabis patients enrolled in an ongoing, longitudinal study).
From: CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure
Cannabinoid use variable | Mean (SD) |
|---|---|
Frequency of use | |
Days per week | 5.95 (1.67) |
Times per day | 1.62 (0.89) |
Total uses per week | 9.99 (6.73) |
Cannabinoid exposure | |
Average THC exposure (mg/week) | |
THC—inhaled1 | 68.24 (111.97) |
THC—oral2 | 42.55 (147.45) |
THC—mucosal3 | 10.33 (15.25) |
THC—skin-based applications4 | 5.11 (9.99) |
Overall THC exposure5 | 43.29 (110.37) |
Average CBD exposure (mg/week) | |
CBD—inhaled6 | 48.39 (111.19) |
CBD—oral7 | 37.33 (54.29) |
CBD—mucosal8 | 214.90 (297.63) |
CBD—skin-based applications4 | 2.22 (1.46) |
Overall CBD exposure5 | 166.69 (258.41) |
